Skip to main content
. Author manuscript; available in PMC: 2015 May 1.
Published in final edited form as: J Pharm Sci. 2014 Mar 14;103(5):1375–1383. doi: 10.1002/jps.23939

Table 6.

Anti-Xa and anti-IIa activity of UFH, LMWH-II and commercial LMWHs.

Heparin Anti-Xa activity (U/mg) Anti-IIa activity (u/mg) Anti-Xa/anti-IIa (ratio)
UFH 201 201 1
LMWH-II 163 ± 4 59 ± 6 2.7
Enoxaparin 170 ± 5 47 ± 4 3.6
Enoxaparin* 184 ± 2 45 ± 3 4.1
Nadroparin* 178 ± 9 67 ± 4 2.7
Dalteparin* 172 ± 6 93 ± 9 2.4
Tinzaparin* 181 ± 7 45 ± 3 3.9
*

Data based on the results from Achour O. et al.21